medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2002, Number 1

<< Back Next >>

Ann Hepatol 2002; 1 (1)

Treatment of nonalcoholic fatty liver disease

Angulo P

Language: Spanish
References: 65
Page: 12-19
PDF size: 102.61 Kb.


Text Extraction

Treatment of patients with nonalcoholic fatty liver disease (NAFLD) has typically been focused on the management of associated conditions such as obesity, diabetes mellitus and hyperlipidemia. NAFLD associated with obesity may resolve with weight reduction, although the benefits of weight loss have been inconsistent. Appropriate control of glucose and lipid levels is always recommended, but not always effective in reversing the liver condition. Results of pilot studies evaluating ursodeoxycholic acid, gemfibrozil, betaine, N-acetylcysteine, vitamin E (a-tocopherol), metformin and thiazolidinedione derivatives suggest that these medications may be of potential benefit for patients with NAFLD. These medications, however, need first to be tested in well-controlled trials with clinically relevant end-points and extended follow up. A better understanding of the pathogenesis and natural history of NAFLD will help to identify the subset of patients at risk of progressing to advanced liver disease, and hence, those patients who should derive the most benefit from medical therapy.


REFERENCES

  1. Ludwig J, Viggiano RT, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 342-348.

  2. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986; 8: 283-286.

  3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002 (in press).

  4. Lee RG. Nonalcoholic steatohepatitis. A study of 49 patients. Hum Pathol 1989; 20: 594-599.

  5. Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: A follow up study of forty-two patients for up to 21 years. Hepatology 1990; 11: 74-80.

  6. Bacon BR, Farahvash MJ, Janney CG, et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107; 1103-1109.

  7. Teli M, Oliver FW, Burt AD, et al. The natural history of nonalcoholic fatty liver: A follow up study. Hepatology 1995; 22: 1714-1717.

  8. Matteoni CA, Younossi ZM, Gramlich TL, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.

  9. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.

  10. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356-1362.

  11. Diehl AM, Goodman Z, Ishak KG. Alcohol-like liver disease in nonalcoholic. A clinical and histological comparison with alcohol-induced liver injury. Gastroenterology 1989; 95: 1056-1060.

  12. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. A Med Scand 1986; 220: 83-88.

  13. Rozental P, Biava C, Spencer H, et al. Liver morphology and function tests in obesity and during total starvation. A J DigDis 1967; 12: 198-208.

  14. Drenick EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass. N Engl J Med 1970; 282: 829-834.

  15. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-1413.

  16. Andersen T, Gluud C, Franzmann MB, et al. Hepatic effects of dietary weight loss in morbidly obese patients. Hepatology 1991; 12: 224-229.

  17. Ueno T, Sugawara H, Sujaku K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. Hepatology 1997; 27: 103-107.

  18. Vajro P, Fontanella A, Perna C, et al. Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994; 125: 239-241.

  19. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997; 42: 1428-1432.

  20. Rashid M, Roberts E. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol and Nutr 2000; 30: 48-53.

  21. Kanders BS, Blackburn GL. Very-low-calorie diets for the treatment of obesity. In: Blackburn GL, Kanders BS (eds) Obesity: Pathophysiology, Psychology and Treatment. New York: Chapman and Hall. 1994: 197-215

  22. Kolanowski J. A risk-benefit assessment of anti-obesity drugs. Drug Safety 1999; 20: 119-131.

  23. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996; 335: 609-616.

  24. Lin HZ, Yang SQ, Chuckaree C, et al. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6: 998-1003.

  25. DeWind LT, Payne JH. Intestinal bypass surgery for morbid obesity. Long term results. JAMA 1976; 236: 2298-2301.

  26. Campbell JM, Hung TK, Karam JH, et al. Jejunoileal bypass as a treatment of morbid obesity. Arch Inter Med 1977: 137: 602-610.

  27. Ackerman NB. Protein supplementation in the management of degenerating liver function after jejunoileal bypass. Surg Gynecol and Obst 1979; 149: 8-14.

  28. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazol, irrespective of protein-calorie malnutrition. Gastroenterology 1982; 82: 535-548.

  29. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition in rats. Gastroenterology 1992; 102: 1363-1370.

  30. Buchman AL, Dubin MD, Moukarzel AA, et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 1995; 22: 1390-1403.

  31. Pappo I, Becovier H, Berry EM, et al. Polymixin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in rat. J Surg Res 1991; 51: 106-112.

  32. Freud HR, Muggia-Sullan M, LaFrance R, et al. A possible beneficial effect of metronidazol in reducing TPN-associated liver function derangements. J Surg Res 1985; 38: 356-363.

  33. Laurin J, Lindor KD, Crippin JS, et al. Ursodeoxycholic acid or clofibrate in the treatment of nonalcohol-induced steatohepatitis: A pilot study. Hepatology 1996; 23: 1464-1467.

  34. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384.

  35. Guma G, Viola L, Thome M, et al. Ursodeoxycholic acid in the treatment of nonalcoholic steatohepatitis: Results of a prospective clinical controlled trial [Abstract]. Hepatology 1997; 26: 387A.

  36. Ceriani R, Bunati S, Morini L, et al. Effect of ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis [Abstract]. Hepatology 1998; 28: 386A.

  37. Holoman J, Glasa J, Kasar J, et al. Serum markers of liver fibrosis in patients with non-alcoholic steatohepatitis (NASH). Correlation to liver morphology and effect of therapy. J Hepatology 2000; 32: 210.

  38. Barak AJ, Beckenhauer HC, Junnila M, et al. Dietary betaine promotes generation of hepatitic S-adenosylmethionine and protects the liver from ethanol-induced fatty infiltration. Alcohol Clin Exp Res 1993; 17: 552-555.

  39. Abdelmalek M, Angulo P, Jorgensen RA, et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96: 2711-2717.

  40. Gulbahar O, Karasu ZA, Ersoz G, et al. Treatment of non-alcoholic steatohepatitis with N-acetylcysteine [Abstract]. Gastroenterology 2000; 118: A1444.

  41. Hasegawa T, Yoneda M, Nakamura K, et al. Long-and short-term d-alpha-tocopherol supplementation inhibits liver collagen alpha-1(I) gene expression [Abstract]. Hepatology 1997; 26: 250A.

  42. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr 2000; 136: 734-738.

  43. Hasegawa T, Yoneda M, Nakamura K, et al. Plasma trnasforming growth factor-b1 level and efficacy of a-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol and Ther 2001; 15: 1667-1672.

  44. Angulo P, Lindor KD. Insulin resistance and mitochondrial abnormalities in NASH: a cool look into a burning issue. Gastroenterology 2001; 120: 1281-1285.

  45. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet Med 1999; 16: 179-192.

  46. Caldwell SH, Hespenheiden EE, Redick JA, et al. A pilot study of thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96: 519-525.

  47. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998; 338: 908-909.

  48. Marchesini G, Brizi M, Bianchi G, et al. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894.

  49. Letterson P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24: 200-208.

  50. Jaeschke H, Wang Y, Essani NA. Reactive oxygen species activate the transcription factor NF-kB in the liver by induction of lipid peroxidation [Abstract]. Hepatology 1996; 24: 238A.

  51. Acosta D, Wenzel DG. Injury produce by free fatty acids to lysosomes and mitochondria in cultures heart muscle and endothelial cells. Atherosclerosis 1974; 20: 417-426.

  52. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111: 1645-1653.

  53. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Investi 2000; 105: 1067-1075.

  54. Weltman MD, Farrel GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998; 27: 128-133.

  55. Schuppan D, Jia JD, Brinkhaus B, et al. Herbal products for liver diseases. A therapeutic challenge for the new millennium. Hepatology 1999; 30: 1099-1104.

  56. Yang SQ, Lin HZ, Lane MD, et al. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. PNAS 1997; 94: 2557-2562.

  57. Chavin KD, Yang SQ, Lin HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem 1999; 274: 5692-5700.

  58. Cortez-Pinto H, Chatham J, Chacko VP, et al. Alterations in liver ATP homeostasis in human nonalcoholic steatoheaptitis. A pilot study. JAMA 1999; 282: 1659-1664.

  59. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998; 114: 311-318.

  60. Boncovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 1999; 31: 421-429.

  61. Younossi ZM, Gramlich T, Bacon BR, et al. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999; 30: 847-850.

  62. Desai TK. Phlebotomy reduces transaminase levels in patients with non-alcoholic steatohepatitis [Abstract]. Gastroenterology 2000; 118: A975.

  63. Nitecki J, Jackson FW, Allen ML, et al. Effect of phlebotomy on non-alcoholic steatohepatitis (NASH) [Abstract]. Gastroenterology 2000; 118: A1474.

  64. Charlton M, Kasparova P, Weston S, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl 2001; 7: 608-614.

  65. Contos MJ, Cales W, Sterling RK, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363-373.




2020     |     www.medigraphic.com